F
railty is a clinical syndrome 1 characterized by low physiological reserves and is strongly associated with vulnerability to functional decline 2, 3 and complications from medical, 4 ,5 percutaneous, 6 and surgical interventions, 7 especially in older adults with cardiovascular disease. 2, 3, 8 Specifically, frailty has been associated with a greater prevalence of adverse outcomes in individuals with heart failure (HF) [9] [10] [11] and in those undergoing cardiac surgery 12, 13 or transcatheter aortic valve replacement. 6, 14 Frailty is determined according to functional capacity, strength, mobility, fatigue, 1 and sometimes mood and cognition, [15] [16] [17] but systematic measurement of frailty has not permeated cardiovascular practice, despite its potential as a risk factor to use to guide selection of candidates for circulatory support. 18 Additionally, frailty is not clinically employed serially to evaluate the effect of interventions.
Although no single therapeutic intervention has been shown to consistently reverse frailty, there is a growing body of clinical evidence from the HF literature suggesting that placement of a left ventricular assist device (LVAD) may reverse several features of frailty, 19 such as improving muscle strength, 20, 21 increasing 6-minute walk distance, 22, 23 and reducing exhaustion. 24, 25 When used as an alternative to heart transplantation, destination therapy LVADs extend and improve the lives of individuals with advanced HF, [25] [26] [27] many of whom are older adults with limited cardiopulmonary reserve, who appear frail. By restoring cardiac output and adequate organ perfusion, LVADs can reverse the catabolic state associated with advanced HF. Return to an anabolic state can result in a reversal of sarcopenia, lack of energy, slow gait speed, exhaustion, and cardiac cachexia, which are all components of the frailty phenotype.
The primary hypothesis of this study was that elective implantation of LVADs in older adults with advanced systolic HF would improve or even reverse frailty. A secondary exploratory hypothesis was that persistence of frailty would be associated with age and other factors (e.g., comorbidities, laboratory results, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) score, procedural factors, serious adverse events (SAEs)).
METHODS

Study Design
We conducted a prospective, multicenter cohort pilot study at five academic medical centers in the Greater New York Geriatric Cardiology Consortium (www.gnygcc.org): Columbia University Medical Center, Mount Sinai Hospital, New York University Medical Center, Weil Cornell University Medical Center, and Thomas Jefferson University. In this study, measurably frail older adults scheduled for LVAD implantation for standard clinical indications were evaluated to determine whether mechanical circulatory support would affect their frailty.
Study Subjects
Study subjects were older adults (≥60) eligible to receive an elective LVAD as destination therapy. Inclusion criteria included frailty (presence of ≥3 frailty criteria (see below), plans for placement of elective ventricular assist device (VAD) (e.g., INTERMACS score ≥2) for clinical indications, and able and willing to provide informed consent. Exclusion criteria included inability to perform required assessments (e.g., nonelective VAD), prior heart transplantation, renal failure requiring dialysis, comorbidities other than advanced heart disease anticipated to limit survival to less than 6 months, active alcohol or substance abuse, and documented nonadherence, which were determined as part of standard LVAD evaluation. All subjects enrolled reviewed and signed informed consent documents. The institutional review boards of each participating institution approved the protocol.
Protocol
Individuals were screened and enrolled up to 4 weeks before LVAD implantation. Informed consent, complete history, physical examination, and medication list were obtained before LVAD implantation. Preoperative testing performed to determine eligibility for LVAD implantation was used as direct eligibility criteria for this study. Subjects completed a frailty evaluation and several questionnaires to assess quality of life (Kansas City Cardiomyopathy Questionnaire), 28 mood (Physician Health Questionnaire (PHQ-9)), energy (anergia scale), 29, 30 and cognitive function (Trail-Making Test Part B), 31 all of which were measured concordantly with frailty evaluations. Frailty was measured according to the Fried criteria: 1 • Unintentional weight loss of more than 10 pounds (not due to diuretic use, dieting, or exercise) or 5% of previous body weight in last year; • Exhaustion, based on response to two questions ("I felt that everything I did was an effort" and "I could not get going"), with a frequency of at least 3 days per week; • Physical activity, based on the short version of the Minnesota Leisure Time Activity questionnaire, with kilocalories per week expended calculated using a standardized algorithm (men expending <383 kcal/wk and women <270 kcal/wk met frailty criteria); • Gait speed, with sex-specific and height cutoffs for the time to walk 15 feet (men: ≤173 cm, ≥7 seconds; >173 cm, ≥6 seconds; women: ≤159 cm, ≥7 seconds; >159 cm, ≥6 seconds); and • Grip strength, stratified according to sex and body mass index (BMI) quartiles as previously published. 1 Subjects were frail if they met 3 or more of the aforementioned criteria.
Statistical Analysis
Study data were collected and managed using REDCap electronic data capture tools hosted at Columbia University. Descriptive statistics were used to characterize study participants. For the primary analysis, we used the Wilcoxon rank sum test to compare frailty components present at baseline with those present 6 months after LVAD implantation. Secondary exploratory analyses focused on how baseline covariates predicted improvement in frailty scores after LVAD implantation. To identify potential baseline characteristics associated with frailty improvement, we used Wilcoxon rank sum tests to compare demographic and clinical factors of those whose frailty did and did not decrease at 6 months. These factors were then evaluated for predictive performance using multivariate logistic regression. To characterize the time course of the change in frailty during the study period, we delineated changes over time in grip strength, weight, physical activity, gait speed, and exhaustion 1, 3, and 6 months after LVAD implantation. We used logistic regression to evaluate the effect of SAEs on changes in frailty, treating the number of SAEs as a continuous predictor of the binary frailty outcome.
RESULTS
The study population ( Figure 1 ) included 50 individuals who were eligible to receive destination therapy LVAD, of whom 42 underwent surgery and eight declined. The 42 subjects enrolled accounted for 59% of individuals aged 60 and older undergoing destination therapy LVAD at the five institutions during the approximately 1.5-year recruitment period. There were 29 subjects enrolled in the longitudinal analysis of frailty 1, 3, and 6 months after LVAD placement; 13 were excluded from the longitudinal analysis because they did not meet inclusion criteria (required urgent LVAD, were not frail, had insufficient data to determine frailty status). Subjects were typical of a population with advanced systolic HF: predominately male with ischemic heart disease, an ejection fraction of less than 20%, and multiple comorbid conditions ( Table 1 ). The cohort that underwent serial frailty assessments did not differ significantly from the other cohorts (Table 1) .
Frailty measures at baseline were not correlated with HeartMate II survival score 32 (coefficient of determination, r 2 = 0.0899, P = .11). Subjects who underwent serial frailty analysis had an average of 3.9 AE 0.9 frailty criteria at baseline and 2.8 AE 1.4 at 6 months (P = .003). There were significant differences in gait speed (0.8 AE 0.2 vs 0.5 AE 0.2 m/ s, P = .02), handgrip strength (26.2 AE 7.8 vs 17.81 AE 10.1 kg/m 2 P = .04), energy expenditure (396.6 AE 159.2 vs 105.5 AE 152.3 kcal/wk, P = .003), exhaustion (12.5% vs 70%, P = .02), and weight loss in the preceding year (0.3 AE 10% vs 14.7%AE14%, P = .03) between subjects who had fewer than 3 frailty criteria after 6 months (n = 9, 47.4%) and those who still had 3 or more. Changes in frailty occurred after 3 to 6 months of LVAD support ( Table 2 ). All subjects continued to meet at least one frailty criterion at each time point.
Decreases in frailty at 6 months were associated with improvements in other measures (Table 3) of quality of life, specifically with subscales of total symptoms, their frequency and burden, and the clinical and overall summary scores but not with changes in mood or cognition. Baseline factors that were associated (P < .1) with a decrease in frailty (Supplementary Table S1 ) included international normalized ratio, creatinine, and estimated glomerular filtration rate (eGFR). In logistic regression analysis, higher eGFR was the only baseline variable that was significantly associated with a decrease in frailty (P = .03); the addition of other predictors did not significantly improve the model.
Participants who had a decrease in frailty had more days alive out of the hospital (165.2 AE 78.6) than those who did not (142.7 AE 55.9), but this was not statistically significant (Supplementary Table S2 ). Because it is plausible that the presence, frequency, and type of adverse events could affect reversal of frailty, we recorded SAEs during the 6 months after LVAD implantation. Twentyfive participants (86.2%) had at least one SAE, and several had multiple, including infection (n = 13), gastrointestinal bleeding (n = 10), hypovolemia (n = 7), decompensated HF (n = 4), death (4), ventricular tachycardia (n = 2), and mental status changes, traumatic fall, and acute kidney injury (n = 1 each). The total number of SAEs and mean number of SAEs tended to be lower in those whose frailty decreased (14 total SAEs, mean 1.6 SAEs per person) than those who remained frail (27 total SAEs, mean 2.7 SAEs per person). In general, SAEs were associated with less likelihood of a decrease in frailty (estimated odds ratio = 0.56, P = .12).
DISCUSSION
The principle findings of this study were that frailty had decreased 6 months after LVAD implantation in approximately half of older adults with advanced HF who were frail before implantation, it took at least 3 months on LVAD support to begin to see improvement in frailty, those in whom frailty decreased experienced significantly greater improvement in quality of life than those in whom frailty did not decrease, and baseline renal dysfunction may be associated with lower chance of a decrease in frailty.
The coalescence of frailty and advanced HF presents a unique opportunity to assess any LVAD-associated improvement in vascular congestion and cardiac output that might improve the slowness, weakness, fatigue, weight loss, and physical inactivity that constitute frailty. A previous study 18 suggested that there may be two forms of frailty: one responsive to LVAD placement and another not as responsive. Our data support this construct. Although the current study population was small, careful and serial assessment of the components of frailty after LVAD surgery demonstrated that approximately half of subjects who survive to 6 months have a decrease in frailty. The improvements in frailty components were of a small but statistically significant magnitude. When viewed in the context of individual criteria, those improvements are clinically meaningful with increases of approximately 0.3 m/s in gait speed, 8.4 gm/kg in handgrip strength, and more than 350 kcal/wk in energy expenditure between those in whom did and did not improve frailty after 6 months of LVAD support. With LVAD implantation, weight loss was the frailty criterion most resistant to change over time, which is in contrast to prior research showing weight gain in individuals undergoing LVAD implantation. 33 This may be related to a short observation period (6 months as opposed to the 1 year used to define frailty), weight fluctuations that occur as a result of volume overload and diuretic use, or some other unmeasured confounder.
The decrease in frailty, which is highly prevalent in older adults with advanced HF, 34, 35 was associated with improvement in quality of life, particularly in subscales related to symptom burden and frequency, which led to an improvement in the overall score. Decreases in frailty after LVAD were not associated with significant differences in measures of mood or cognition. The absence of any association between decreases in frailty and mood or cognition may be related to the low rates of mood disorders and cognitive dysfunction in our population. On average subjects had evidence of depressive symptoms at baseline, but they were mild. Similarly, although Trail-Making Test Part B results were prolonged, when accounting for education and age, 31 the decrements in executive function were not severe. More-severe cognitive dysfunction and mood disorders may be underrepresented in this cohort because these are considered relative contraindications for LVAD implantation. In addition, a more-sensitive instrument, such as the Montreal Cognitive Assessment, might have identified milder degrees of cognitive impairment.
Although the study population recruited was too small to meaningfully evaluate the effect of residual frailty on survival, length of stay during the implantation procedure was longer, and there were fewer days alive out of the hospital, albeit not statistically significantly so, in those who remained frail than in those in whom frailty decreased. Similarly, those who remained frail tended to have more total and median number of SAEs resulting in rehospitalization. It is possible that frailty that is not responsive to LVAD therapy contributed to these events or that such events impeded or delayed a decrease in frailty. 36 We hypothesized that factors such as age, comorbidities, laboratory parameters, and INTERMACS score at baseline could be used to identify the subgroup of frail older adults with HF who receive a LVAD and remain frail, but age, sex, INTERMACS score, and nutritional state, as evidenced by serum albumin levels, did not differ significantly at baseline between those who had a decrease in frailty and those who did not. Previous studies have observed a lack of association between age and frailty in individuals with advanced HF. 34, 35 The present finding that age is not associated with a decrease in frailty after LVAD implantation further supports the concept that biological age is a more-robust determinant of outcomes than chronological age. 37 The only parameter that was independently associated with a decrease in frailty was a higher baseline eGFR. This finding is consistent with the growing body of evidence linking renal dysfunction with frailty. 38 Chronic kidney disease (CKD) affects 45% of persons aged 70 and older and is associated with changes in systems that have been implicated in the causal chain of frailty, including muscle and bone, 39 nutritional, 40 inflammatory 41 , and vascular. 42 CKD is an independent contributor to decline in physical and cognitive functions in older adults and can double the risk of physical impairment, cognitive dysfunction, and frailty. 43 Accordingly, concomitant renal dysfunction in advanced HF may be an important factor related to decreases in frailty with LVAD implantation.
Decreases in frailty take time, with observed changes seen after months of LVAD support. This is similar to the effects of beta-blockers on ejection fraction in individuals with systolic HF, which were consistent with a biological and not pharmacological effect. 44, 45 Such effects are consistent with the complex biological underpinnings of frailty, including inflammatory, metabolic, and nutritional factors, which may be partly addressed by LVAD implantation, through restoration of cardiac output. It is possible that, with longer follow-up, greater improvements in frailty would have been observed because the percentage of frail and prefrail individuals were still improving from 3 to 6 months of LVAD support (Table 2) . Although these results suggest that implantation of an LVAD and restoration of cardiac output can lead to decreases in frailty, our findings also suggest that this intervention alone will not completely reverse frailty or even improve frailty in a large portion of older, frail LVAD recipients. What then could be used to further address frailty in this population? Continuous focused attention using targeted interventions such as physical rehabilitation and nutritional supplementation appear promising. Given the known benefits of cardiac rehabilitation programs for subjects with cardiovascular disease undergoing procedures such as coronary artery bypass grafting, 46 percutaneous coronary intervention, 47 and percutaneous or surgical valve replacement, 48 the opportunity to routinely include cardiac rehabilitation after LVAD implantation is worthy of additional study because it may address the unmet need of residual frailty and poor function in these individuals. A small randomized trial 49 showed greater improvement in Kansas City Cardiomyopathy Questionnaire scores and leg strength in subjects receiving cardiac rehabilitation after LVAD implantation than in controls. Novel physical rehabilitation interventions specifically designed for older, frail adults with HF in the early stages of recovery also appear promising. 50 If larger trials confirm that such interventions are effective, 51 then in the era of bundled payments and a focus on quality, it is conceivable that cardiac rehabilitation would become a standard intervention after LVAD implantation. The timing and structure of such an approach could be based on serial measurements of frailty.
There are multiple limitations to this multicenter pilot study, including the small number of subjects enrolled, which limits statistical power (potentially resulting in a type II error) and hampers subgroup analyses. Although LVAD use is becoming more widespread, 27 including in older adults, 52 our inclusion criteria of aged 60 and older (which were modified from an initial cutoff of 65) limited the population available for study at the five institutions. Although the multicenter nature of the study facilitated recruitment, it also introduced heterogeneity, although most programs use criteria for LVAD implantation that the Centers for Medicare and Medicate Services and the International Society of Heart and Lung Transplantation have specified. 53 The relatively short-term nature of the study (6 months) does not allow any conclusions to be made about whether longer-term support would provide more benefit in terms of frailty improvement or reversal. Additionally, we employed the Fried Frailty Index as the primary outcome measure, which is focused on physical function, but also included measure of cognition and mood, albeit with measures that have not been extensively validated in this population. Finally, the inability to measure frailty in all subjects at each time period despite dedicated study personnel speaks to the difficulty of incorporating conventional frailty measures in clinical practice in this population with advanced HF and other competing priorities. These missing data could introduce potential bias in our results, resulting in a type I error.
In conclusion, decreases in frailty are seen after 6 months of LVAD support, in approximately half of older adults with advanced systolic HF and concomitant frailty who are having a LVAD placed for standard clinical indications. Improvements in frailty measures were associated with other domains (e.g., quality of life) and a trend toward fewer rehospitalizations, suggesting that strategies to enhance frailty reversal in this population are worthy of additional study.
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